April 17, 2019 10:44 AM EDTUpdated 10:59 AM
News Briefing

Turn­ing Point un­veils $166M IPO; Aque­s­tive's rilu­zole film prod­uct is ac­cept­ed for FDA re­view

John Carroll

Editor & Founder

→ San Diego-based Turn­ing Point Ther­a­peu­tics has hit the high end of the range it set for their IPO, pric­ing an up­sized set of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Bris­tol My­ers launch­es fresh round of ma­jor cost cuts in bid to get ahead of patent cliff

Lil­ly posts 45% sales jump, culls four pro­grams across obe­si­ty, Alzheimer's, heart fail­ure and eczema

As­traZeneca of­fers some de­tail on Chi­na probe, reaf­firms com­mit­ment to that mar­ket

No­vo Nordisk is feel­ing the com­pe­ti­tion from com­pound­ed GLP-1s, ex­ec says

Small per­son­al­ized vac­cine tri­al sees progress in late-stage kid­ney can­cer

Ku­ra's AML drug pass­es key study in ad­vanced pa­tients, plans next steps with FDA and new­ly di­ag­nosed stud­ies

A service from the Financial Times